Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: The SWING study

详细信息    查看全文

• 作者：Matthew Reaney ; Katarzyna Cypryk ; Nicholas Tentolouris ; Michael Jecht ; Simon Cleall ; Ute Petzinger ; Veikko Koivisto
• 关键词：Diabetes mellitus ; Type 2 ; Insulin ; Analogue ; Lispro ; Aspart
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2012
• 出版时间：August, 2012
• 年：2012
• 卷：97
• 期：2
• 页码：231-241
• 全文大小：492 K

文摘

Aim

SWING was a prospective, observational study conducted in nine European countries primarily to assess direct treatment costs when switching from short-acting human insulins to rapid-acting insulin analogues (H-A) or vice versa (A-H) in patients with type 2 diabetes.

Methods

Data were collected at a baseline visit (time of switch) and at approximately 3, 6 and 12 months post-switch.

Results

In total, 2389 patients switched from H-A (n = 2203) or A-H (n = 186); another 603 were enrolled but ineligible. Mean (SD) direct diabetes-related costs (pro-rated to account for variable visit schedules) were €548.7 (865.8) 6 months prior to switch, €625.6 (1474.9) at 0-6 months and €568.6 (590.7) 6-12 months following switch for H-A, and €544.5 (421.0), €481.0 (301.5) and €461.6 (335.0) for A-H, respectively. Mean (SD) HbA_1c decreased over 12 months by 1.08 (1.53) % units H-A and 1.17 (1.45) % units A-H. A small decline in hypoglycaemia occurred over time, but there were no clinically meaningful changes in mean PROs.

Conclusions

There were small changes in mean direct diabetes-related costs (following adjustment for time interval) in patients switching in either direction. Improvements in mean HbA_1c and incidence of hypoglycaemia cannot necessarily be attributed to therapeutic switch.